急性呼吸衰竭中吸入一氧化氮与依前列醇的比较:一项观察性目标试验模拟
该研究利用美国Premier Healthcare Database,纳入接受机械通气的成人急性呼吸衰竭或ARDS患者,比较初始吸入一氧化氮与依前列醇的实践模式和有效性。在11,200例患者(303家医院)中,56.8%首先接受一氧化氮,42.1%首先接受依前列醇,1.0%同日接受两者;104家医院(34.3%)仅用一氧化氮,118家医院(38.9%)仅用依前列醇。通过限制分析于仅使用单一药物的医院,采用多变量Fine-Grey竞争风险模型(竞争事件为死亡或临终关怀出院)分析成功拔管,发现两组成功拔管可能性无差异(SHR 0.97,95%CI 0.80-1.18),总住院费用和死亡也无差异,结果经多种敏感性分析稳健。
要点
- 在11,200例机械通气急性呼吸衰竭或ARDS成人中,56.8%首先接受吸入一氧化氮,42.1%首先接受吸入依前列醇,1.0%同日接受两者。
- 仅用一氧化氮医院(104家,1,666例)与仅用依前列醇医院(118家,1,812例)的患者成功拔管可能性无差异(SHR 0.97,95%CI 0.80-1.18)。
- 两组总住院费用和死亡均无差异。
- 美国各医院在初始吸入血管扩张剂选择上存在很大差异。
- 结果经多种敏感性分析稳健。
适用人群与场景
- 美国Premier Healthcare Database中接受机械通气并开始吸入一氧化氮、依前列醇或两者的成人急性呼吸衰竭或ARDS患者。
- 限制分析于仅使用吸入一氧化氮或仅使用吸入依前列醇的医院。
研究设计与关键结果
- 研究类型:观察性目标试验模拟,利用美国Premier Healthcare Database,纳入11,200例成人患者(303家医院)。
- 实践模式:6,366例(56.8%)首先接受吸入一氧化氮,4,720例(42.1%)首先接受吸入依前列醇,114例(1.0%)同日接受两者。
- 医院层面:104家医院(34.3%;1,666例)仅使用一氧化氮,118家医院(38.9%;1,812例)仅使用依前列醇。
- 主要终点:成功拔管,采用多变量Fine-Grey竞争风险(死亡或临终关怀出院)时间-事件模型分析;仅用一氧化氮医院 vs 仅用依前列醇医院的患者成功拔管可能性无差异(亚分布风险比0.97;95%CI 0.80-1.18)。
- 次要终点:总住院费用和死亡均无差异。
- 结果经多种敏感性分析稳健。
证据类型、等级与局限
- 证据类型:观察性目标试验模拟。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The inhaled vasodilators nitric oxide and epoprostenol may be initiated to improve oxygenation in mechanically ventilated patients with severe acute respiratory failure (ARF); however, practice patterns and head-to-head comparisons of effectiveness are unclear.
RESEARCH QUESTION: What are the practice patterns and comparative effectiveness for inhaled nitric oxide and epoprostenol in severe ARF?
STUDY DESIGN AND METHODS: Using a large US database (Premier Healthcare Database), we identified adult patients with ARF or ARDS who were mechanically ventilated and started on inhaled nitric oxide, epoprostenol, or both. Leveraging large hospital variation in the choice of initial inhaled vasodilator, we compared the effectiveness of inhaled nitric oxide with that of epoprostenol by limiting analysis to patients admitted to hospitals that exclusively used either inhaled nitric oxide or epoprostenol. The primary outcome of successful extubation was modeled using multivariate Fine-Grey competing risk (death or hospice discharge) time-to-event models.
RESULTS: Among 11,200 patients (303 hospitals), 6,366 patients (56.8%) received inhaled nitric oxide first, 4,720 patients (42.1%) received inhaled epoprostenol first, and 114 patients (1.0%) received both therapies on the same day. One hundred four hospitals (34.3%; 1,666 patients) exclusively used nitric oxide and 118 hospitals (38.9%; 1,812 patients) exclusively used epoprostenol. No differences were found in the likelihood of successful extubation between patients admitted to nitric oxide-only hospitals vs those admitted to epoprostenol-only hospitals (subdistribution hazard ratio, 0.97; 95% CI, 0.80-1.18). Also no differences were found in total hospital costs or death. Results were robust to multiple sensitivity analyses.
INTERPRETATION: Large variation exists in the use of initial inhaled vasodilator for respiratory failure across US hospitals. Comparative effectiveness analyses identified no differences in outcomes based on inhaled vasodilator type.
参考来源
- Bosch NA, Law AC, Vail EA, et al. Inhaled Nitric Oxide vs Epoprostenol During Acute Respiratory Failure: An Observational Target Trial Emulation. Chest. 2022. PMID: 35952768. doi:10.1016/j.chest.2022.08.001
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。